Delivering cytokines at tumor site: The immunocytokine-conjugated anti-EDB-fibronectin antibody case.

摘要: Although considerable efforts have been made in the discovery of new agents for cancer treatment, several promising therapeutics cannot be applied systemically because their severe side effects. This is case various recombinant pro-inflammatory cytokines that, despite potent anti-cancer activity, can not find way to clinical exploitation due devastating toxicity shown during dose escalation therapeutically active concentrations. To circumvent these problems, an elegant and efficient accumulate therapeutic at tumor site, thus reducing systemic effects, conjugation tumor-specific antibodies. Here, we review preclinical data about immunocytokines conjugated a single-chain human antibody that selectively targets tumor-associated stroma blood vessels by binding with high affinity specificity extra domain-B (EDB) fibronectin.